aspartic acid has been researched along with Hepatitis B, Chronic in 8 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Hepatitis B, Chronic: INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Enzymatic analysis of aspartate/alanine aminotransferase (AST/ALT) does not exactly represent the progression of liver fibrosis or inflammation." | 7.96 | Immunological measurement of aspartate/alanine aminotransferase in predicting liver fibrosis and inflammation. ( Baik, GH; Bang, CS; Choi, EY; Ham, YL; Kim, DJ; Kim, HJ; Kim, SY; Shin, SP; Suk, KT; Yang, YJ, 2020) |
| "A total of 319 chronic hepatitis B patients who received lamivudine therapy for more than a year were enrolled in this study." | 7.78 | Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment. ( Wu, F; Wu, MJ; Zhu, B; Zhu, SM; Zhuge, XL, 2012) |
| "Enzymatic analysis of aspartate/alanine aminotransferase (AST/ALT) does not exactly represent the progression of liver fibrosis or inflammation." | 3.96 | Immunological measurement of aspartate/alanine aminotransferase in predicting liver fibrosis and inflammation. ( Baik, GH; Bang, CS; Choi, EY; Ham, YL; Kim, DJ; Kim, HJ; Kim, SY; Shin, SP; Suk, KT; Yang, YJ, 2020) |
| "In the current study we aimed to show the common YMDD motif mutations in viral polymerase gene in chronic hepatitis B patients during lamivudine and adefovir therapy." | 3.79 | Prevelance of common YMDD motif mutations in long term treated chronic HBV infections in a Turkish population. ( Alagozlu, H; Coskun, M; Koksal, B; Ozdemir, O; Yilmaz, A, 2013) |
| "A total of 319 chronic hepatitis B patients who received lamivudine therapy for more than a year were enrolled in this study." | 3.78 | Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment. ( Wu, F; Wu, MJ; Zhu, B; Zhu, SM; Zhuge, XL, 2012) |
| "To establish a rapid and accurate method for the detection of lamivudine-resistant mutations in hepatitis B virus and monitor of lamivudine resistance during lamivudine treatment in patients with chronic hepatitis B virus infection." | 3.73 | Detection of YMDD mutants using universal template real-time PCR. ( Han, B; Wang, RS; Yang, ZJ; Zhang, H; Zhu, YF, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Wai-Sun Wong, V | 1 |
| Kao, JH | 1 |
| Li, ZC | 1 |
| Li, Z | 1 |
| Li, C | 1 |
| Fang, JC | 1 |
| Li, XZ | 1 |
| Zhao, YN | 1 |
| Liang, CY | 1 |
| Kim, HJ | 1 |
| Kim, SY | 1 |
| Shin, SP | 1 |
| Yang, YJ | 1 |
| Bang, CS | 1 |
| Baik, GH | 1 |
| Kim, DJ | 1 |
| Ham, YL | 1 |
| Choi, EY | 1 |
| Suk, KT | 1 |
| Alagozlu, H | 1 |
| Ozdemir, O | 1 |
| Koksal, B | 1 |
| Yilmaz, A | 1 |
| Coskun, M | 1 |
| Wu, F | 1 |
| Wu, MJ | 1 |
| Zhuge, XL | 1 |
| Zhu, SM | 1 |
| Zhu, B | 1 |
| Shindo, M | 1 |
| Hamada, K | 1 |
| Nishioji, K | 1 |
| Muramatsu, A | 1 |
| Oda, Y | 1 |
| Okuno, T | 1 |
| Yuen, MF | 1 |
| Wong, DK | 1 |
| Sum, SS | 1 |
| Yuan, HJ | 1 |
| Yuen, JC | 1 |
| Chan, AO | 1 |
| Wong, BC | 1 |
| Lai, CL | 1 |
| Wang, RS | 1 |
| Zhang, H | 1 |
| Zhu, YF | 1 |
| Han, B | 1 |
| Yang, ZJ | 1 |
1 trial available for aspartic acid and Hepatitis B, Chronic
| Article | Year |
|---|---|
Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection.
Topics: Adolescent; Adult; Amino Acid Motifs; Anti-HIV Agents; Aspartic Acid; DNA, Circular; DNA, Viral; Fem | 2005 |
7 other studies available for aspartic acid and Hepatitis B, Chronic
| Article | Year |
|---|---|
Letter: elevated aspartate aminotransferase and aspartate aminotransferase to alanine aminotransferase ratio predicts poor survival in hepatocellular carcinoma after resection-Authors' reply.
Topics: Alanine Transaminase; Asia, Eastern; Aspartate Aminotransferases; Aspartic Acid; Carcinoma, Hepatoce | 2020 |
Letter: elevated aspartate aminotransferase and aspartate aminotransferase to alanine aminotransferase ratio predicts poor survival in hepatocellular carcinoma after resection.
Topics: Alanine Transaminase; Asia, Eastern; Aspartate Aminotransferases; Aspartic Acid; Carcinoma, Hepatoce | 2020 |
Immunological measurement of aspartate/alanine aminotransferase in predicting liver fibrosis and inflammation.
Topics: Alanine; Alanine Transaminase; Aspartate Aminotransferases; Aspartic Acid; Biomarkers; Biopsy; Hepat | 2020 |
Prevelance of common YMDD motif mutations in long term treated chronic HBV infections in a Turkish population.
Topics: Adenine; Adult; Aged; Amino Acid Motifs; Anti-HIV Agents; Antiviral Agents; Aspartic Acid; Case-Cont | 2013 |
Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment.
Topics: Adult; Aged; Alanine Transaminase; Amino Acids; Antiviral Agents; Aspartic Acid; China; DNA, Viral; | 2012 |
The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartic Acid; DNA, Viral; Drug Resistance, Viral; Fe | 2004 |
Detection of YMDD mutants using universal template real-time PCR.
Topics: Antiviral Agents; Aspartic Acid; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Hepati | 2006 |